Bergen, Norway, 2 September 2019.

BerGenBio ASA (the"Company") (OSE: BGBIO). Reference is made to the stock
exchange notice dated 28 August 2019 and primary insiders exercise of share
options which expire in 2019.
Primary Insider Richard Godfrey (CEO) exercised 225,000 options equal to 225,000
shares. To cover costs related to the exercise, Richard Godfrey transferred his
rights to receive shares resulting from the exercise of options to a third
party. A total of 177,366 shares were sold at an average price of NOK 13.94 and
Richard Godfrey received the remaining 47,634 shares. Following the transaction,
Richard Godfrey holds 215,449 shares in the Company through Gnist Holding AS and
holds 1,129,284 unexercised options in the Company.

Primary Insider James Lorens (CSO) exercised 150,000 options equal to 150,000
shares. To cover costs related to the exercise, James Lorens transferred his
rights to receive shares resulting from the exercise of options to a third
party. A total of 119,961 shares were sold at an average price of NOK 13.94 and
James Lorens received the remaining 30,039 shares. Following the transaction,
James Lorens holds 280,039 shares in the Company and holds 588,507 unexercised
options in the Company.

Primary Insider Endre Kjærland (Associate Director of IP and Contracts)
exercised 15,000 options equal to 15,000 shares. To cover costs related to the
exercise, Endre Kjærland transferred his rights to receive shares resulting from
the exercise of options to a third party. A total of 13,246 shares were sold at
an average price of 13.94 and Endre Kjærland received the remaining 1,754
shares. Following the transaction, Endre Kjærland holds 3,262 shares in the
Company and holds 88,525 unexercised options in the Company.

-End-

Contacts

Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the
expectations expressed or implied in this announcement by such forward-looking
statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.